225 related articles for article (PubMed ID: 34609050)
1. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress.
Tai Y; Zhao C; Zhang L; Tang S; Jia X; Tong H; Liu R; Tang C; Gao J
J Cell Mol Med; 2021 Nov; 25(22):10389-10402. PubMed ID: 34609050
[TBL] [Abstract][Full Text] [Related]
2. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
3. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension.
Martínez-Revelles S; Avendaño MS; García-Redondo AB; Alvarez Y; Aguado A; Pérez-Girón JV; García-Redondo L; Esteban V; Redondo JM; Alonso MJ; Briones AM; Salaices M
Antioxid Redox Signal; 2013 Jan; 18(1):51-65. PubMed ID: 22671943
[TBL] [Abstract][Full Text] [Related]
5. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
6. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats.
Yang YY; Lee TY; Huang YT; Chan CC; Yeh YC; Lee FY; Lee SD; Lin HC
Liver Int; 2012 Jan; 32(1):48-57. PubMed ID: 22098317
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.
Gao JH; Wen SL; Yang WJ; Lu YY; Tong H; Huang ZY; Liu ZX; Tang CW
PLoS One; 2013; 8(7):e69309. PubMed ID: 23922700
[TBL] [Abstract][Full Text] [Related]
10. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.
Fiorucci S; Distrutti E
Pharmacol Res; 2016 Sep; 111():749-756. PubMed ID: 27475883
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling.
Al-Rashed F; Calay D; Lang M; Thornton CC; Bauer A; Kiprianos A; Haskard DO; Seneviratne A; Boyle JJ; Schönthal AH; Wheeler-Jones CP; Mason JC
Sci Rep; 2018 Apr; 8(1):6271. PubMed ID: 29674687
[TBL] [Abstract][Full Text] [Related]
12. Polyphenol-Rich Blackcurrant Juice Prevents Endothelial Dysfunction in the Mesenteric Artery of Cirrhotic Rats with Portal Hypertension: Role of Oxidative Stress and the Angiotensin System.
Rashid S; Idris-Khodja N; Auger C; Kevers C; Pincemail J; Alhosin M; Boehm N; Oswald-Mammosser M; Schini-Kerth VB
J Med Food; 2018 Apr; 21(4):390-399. PubMed ID: 29569976
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib induces heme oxygenase-1 expression in macrophages and vascular smooth muscle cells via ROS-dependent signaling pathway.
Wang JS; Ho FM; Kang HC; Lin WW; Huang KC
Naunyn Schmiedebergs Arch Pharmacol; 2011 Feb; 383(2):159-68. PubMed ID: 21174079
[TBL] [Abstract][Full Text] [Related]
14. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
15. PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.
Rodríguez-Vilarrupla A; Laviña B; García-Calderó H; Russo L; Rosado E; Roglans N; Bosch J; García-Pagán JC
J Hepatol; 2012 May; 56(5):1033-1039. PubMed ID: 22245887
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology and a Rational Basis of Therapy.
Gracia-Sancho J; Maeso-Díaz R; Bosch J
Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
[TBL] [Abstract][Full Text] [Related]
17. NADPH oxidase 1/4 inhibition attenuates the portal hypertensive syndrome via modulation of mesenteric angiogenesis and arterial hyporeactivity in rats.
Deng W; Duan M; Qian B; Zhu Y; Lin J; Zheng L; Zhang C; Qi X; Luo M
Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):255-265. PubMed ID: 30413372
[TBL] [Abstract][Full Text] [Related]
18. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
[TBL] [Abstract][Full Text] [Related]
19. The beneficial effects of curcumin in cirrhotic rats with portal hypertension.
Hsu SJ; Lee JY; Lin TY; Hsieh YH; Huang HC; Lee FY; Lin HC; Hou MC; Lee SD
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29162665
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing β-catenin signalling pathway in experimental liver fibrosis.
Zhang L; Tai Y; Zhao C; Ma X; Tang S; Tong H; Tang C; Gao J
J Cell Mol Med; 2021 Aug; 25(16):7993-8005. PubMed ID: 34145945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
